Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
22.79
-0.64 (-2.73%)
Aug 31, 2026, 12:42 PM EDT - Market open
Bicara Therapeutics Employees
Bicara Therapeutics had 103 employees as of December 31, 2025. The number of employees increased by 48 or 87.27% compared to the previous year.
Employees
103
Change (1Y)
48
Growth (1Y)
87.27%
Revenue / Employee
n/a
Profits / Employee
-$1,799,641
Market Cap
1.51B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 103 | 48 | 87.27% |
| Dec 31, 2024 | 55 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 749 |
| Innoviva | 159 |
| Maze Therapeutics | 141 |
| Absci | 140 |
| Tyra Biosciences | 87 |
| ArriVent BioPharma | 77 |
| Avalyn Pharma | 55 |
BCAX News
- 12 days ago - BMO starts Bicara at Outperform, sees meaningful upside potential - TheFly
- 12 days ago - Bicara Therapeutics initiated with an Outperform at BMO Capital - TheFly
- 14 days ago - Bicara Therapeutics price target lowered to $34 from $35 at BofA - TheFly
- 14 days ago - Bicara Therapeutics price target raised to $20 from $18 at Goldman Sachs - TheFly
- 14 days ago - Bicara Therapeutics price target raised to $39 from $28 at BTIG - TheFly
- 14 days ago - Bicara Therapeutics price target raised to $20 from $18 at Mizuho - TheFly
- 14 days ago - Bicara Therapeutics price target raised to $33 from $30 at Wedbush - TheFly
- 14 days ago - Bicara Therapeutics price target raised to $39 from $37 at Morgan Stanley - TheFly